Immunological effects of High-Intensity Focused Ultrasound (HIFU) in Prostate Cancer

Immunological effects of High-Intensity Focused Ultrasound (HIFU) in Prostate Cancer - Immunological effects of High-Intensity Focused Ultrasound (HIFU) in Prostate Cancer

Status

Recruiting

Phases

Unknown

Study type

Observational

Source

JPRN

Registry ID

JPRN-UMIN000060159

Enrollment

Registered

2025-12-24

Start date

2025-11-18

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Prostate cancer

Interventions

None listed

Eligibility

Sex/Gender

Male

Inclusion criteria

Inclusion criteria: 1. Patients diagnosed with non-metastatic prostate cancer who, after receiving a thorough explanation of treatment options from their attending physician, have chosen either HIFU or RARP; and patients diagnosed with benign prostatic hyperplasia who, after receiving a thorough explanation of treatment options from their attending physician, have chosen TUR-P. 2. Individuals with a PSA level below 20 ng/mL. 3. Individuals who, after receiving sufficient explanation regarding participation in this study, have provided written informed consent of their own free will.

Exclusion criteria

Exclusion criteria: 1. Individuals receiving hormonal therapy. 2. Individuals from whom informed consent could not be obtained. 3. Other individuals deemed inappropriate for the study by the principal investigator or sub-investigators.

Design outcomes

Primary

Measure	Time frame
Temporal changes in antitumor immune responses before and after each treatment modality	—

Countries

Japan

Contacts

Public ContactKumpei Takahashi

Tokai University Hospital Department of Urology

t-kumpee@tokai.ac.jp0463-93-1121

Outcome results